Nuformix
GBX0.16
4
-GBX0.02-11.43% Friday 15:25
Statistik
Harga Tertinggi Hari
0.19
Harga Terendah Hari
0.16
52M Tertinggi
0.44
52M Terendah
0.15
Volum
5,008,363
Volum Purata
4,293,815
Kapasiti Pasaran
1.31M
Nisbah P/E
-
Pendapatan Dividen
-
Dividen
-
Akan Datang
Pendapatan
27NovDijangka
EPS yang dijangka
N/A
EPS sebenar
N/A
Orang Lain Juga Mengikuti
Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti NFX.LSE. Ini bukan cadangan pelaburan.
Peserta
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
Astrazeneca
AZN.LSE
Kapasiti Pasaran205.78B
GSK
GSK.LSE
Kapasiti Pasaran67.59B
Synairgen
SNG.LSE
Kapasiti Pasaran8.1M
HUTCHMED (China) Limited
HCM.LSE
Kapasiti Pasaran2.27B
Indivior
INDV.LSE
Kapasiti Pasaran1.23B
Mengenai
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Show more...
CEO
Dr. Daniel John Gooding
Pekerja
3
Negara
GB
ISIN
GB00BYW79Y38